Joseph Kim J. , Ph.d

Biography

Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr. Kim co-founded ADViSYS Inc., a subsidiary of Viral Genomix in 1997 and served as its Chief Executive Officer and President. He co-founded VGX Pharmaceuticals, LLC (Formerly Viral Genomix, Inc) in 2000 and served as its Chief Executive Officer and President from 2000 to June 1, 2009. Dr. Kim is a veteran of the biopharmaceutical industry. Dr. Kim joined VGX Pharmaceuticals from Merck & Co. He has over 10 years of experience in the field of biopharmaceuticals, with a focus on drug and vaccine development. He serves as the Chairman of VGX Animal Health, Inc. He has been Director of Inovio Biomedical Corp since June 1, 2009. He served as Director of ADViSYS Inc. Dr. Kim served as Director of VGX Pharmaceuticals, LLC from 2000 to June 1, 2009. In 2002, Dr. Kim has been named one of the world’s top 100 young innovators by Technology Review magazine. The “TR100”, as this group is called was chosen by a very distinguished Panel of Judges (which includes 2 Nobel Prize Laureates). Recently, he has been selected for the “40 under 40” by the Philadelphia Business Journal as one of the 40 most dynamic professionals who are under 40 years of age in the region. Dr. Kim was also selected on the list of the “50 Most Influential Men“ in the October 2003 and in the October 2006 “Power Issue“ of Details Magazine. He was featured in the “Who's Next 2005“ issue of Newsweek International. In 2006, Dr. Kim has been named a Young Global Leader by the Forum of Young Global Leaders, an affiliate of the World Economic Forum. He was among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries. Dr. Kim has been a Director at Inovio Pharmaceuticals, Inc. since June 1, 2009. Dr. Kim is a veteran of the biopharmaceutical industry. He was trained in economics, engineering and biological sciences at MIT where he was a Robert C. Byrd Federal Honors Scholar. Dr. Kim holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School

Research Interest

Healthcare